Shareholder Alert: Ademi LLP investigates whether Amedisys, Inc. has obtained a Fair Price in its transaction with Option Care Health

MILWAUKEE, May 3, 2023 /PRNewswire/ -- Ademi LLP is investigating Amedisys (NASDAQ: AMED) for possible breaches of fiduciary duty and other violations of law in its transaction with Option Care Health. 

Click here to learn how to join the action https://www.ademilaw.com/case/amedisys-inc or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

Amedisys shareholders are expected to receive only 3.0213 shares of Option Care Health common stock for each share of Amedisys common stock they hold at the closing of the transaction, the equivalent of $97.38 per Amedisys share based on Option Care Health's closing stock price on May 2, 2023. The transaction agreement unreasonably limits competing bids for Amedisys by imposing a significant penalty if Amedisys accepts a superior bid. Amedisys insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Amedisys' board of directors, and whether they are (i) fulfilling their fiduciary duties to all shareholders, and (ii) obtaining a fair and reasonable price for Amedisys.

If you own Amedisys common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or https://www.ademilaw.com/case/amedisys-inc.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.

Contacts

Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

SOURCE Ademi LLP